AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
TransCode's TTX-MC138 Enters Phase 2a Trial in Quantum Leap PRE-I-SPY Platform
ByAinvest
Friday, Dec 12, 2025 9:30 am ET1min read
TransCode Therapeutics and Quantum Leap Healthcare Collaborative have announced a collaboration to evaluate TTX-MC138 in a Phase 2a trial. TTX-MC138, a therapeutic candidate designed to inhibit microRNA-10b, a biomarker linked to metastatic cancers, achieved its primary safety endpoint and established a recommended Phase 2 dose in its Phase 1a trial. The Phase 2a study will enroll up to 45 patients with colorectal cancer who have completed standard therapy but remain ctDNA-positive, indicating minimal residual disease. The study aims to evaluate the biological and clinical activity of TTX-MC138 in the MRD setting.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet